H.R. 2821 · 119th Congress
FDA Modernization Act 3.0
Status: Passed House
- Introduced (done)
- Committee (done)
- Passed House (current)
- Passed Senate
- To President
- Law
Latest action
: Received in the Senate.
Summary
FDA Modernization Act 3.0
This bill requires the Food and Drug Administration (FDA) to publish an interim final rule implementing a provision of the Consolidated Appropriations Act of 2023 that authorized the use of certain alternatives to animal testing to support investigational use of a new drug.
The rule must replace references to animal tests, data, studies, models, and research with references to nonclinical tests, data, studies, models, and research throughout the FDA’s regulations governing investigational new drug applications.
The rule must be published within one year of the bill’s enactment, and must take immediate effect as an interim final rule.
Summary by the Congressional Research Service.
Actions
- Senate
Received in the Senate.
- House
Motion to reconsider laid on the table Agreed to without objection.
- House
On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H4639)
- House
DEBATE - The House proceeded with forty minutes of debate on H.R. 2821.
- House
Considered under suspension of the rules. (consideration: CR H4639-4640)
- House
Mr. Guthrie moved to suspend the rules and pass the bill.
- House
Placed on the Union Calendar, Calendar No. 614.
- House
Reported by the Committee on Energy and Commerce. H. Rept. 119-706.
- House
Ordered to be Reported by the Yeas and Nays: 44 - 0.
- House
Committee Consideration and Mark-up Session Held
- House
Forwarded by Subcommittee to Full Committee by Voice Vote.
- House
Subcommittee Consideration and Mark-up Session Held
Show 3 earlier actions
- House
Referred to the Subcommittee on Health.
- House
Referred to the House Committee on Energy and Commerce.
Introduced in House